ACHN: Summary for Achillion Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 2:33am EST - Canadian Markets open in 6 hours and 57 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Achillion Pharmaceuticals, Inc. (ACHN)

On Feb 9: 2.37 USD

0.05 (2.07%)

MORE ON ACHN

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Achillion Pharmaceuticals, Inc. (NGM:ACHN) Delayed quote data

Last Trade:	2.37 USD
Trade Time:	Feb 9
Change:	0.05 (2.07%)
Prev Close:	2.42
Open:	2.46
Bid:	2.28 x 500
Ask:	2.54 x 500
1y Target Est:	10.50

Day's Range:	2.32 - 2.51
52wk Range:	1.10 - 3.89
Volume:	344,536
Avg Vol (3m):	706,902
Market Cap:	63.17M
P/E (ttm):	N/A
EPS (ttm):	-2.20
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add ACHN to Portfolio

Download Data

HEADLINES

•	China Biotech Week in Review: New Investments in Life Science
	at Seeking Alpha (Mon, Feb 8)

•	Achillion Pharma Out-Licensed China Rights for HIV, Hepatitis Treatment
	at Seeking Alpha (Thu, Feb 4)

•	ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Wed, Feb 3)

•	Ann Taylor, Lexmark, Achillion Pharma big movers
	AP (Tue, Feb 2)

•	Movers roundup: Rudolph Technologies, Hologic
	AP (Tue, Feb 2)

•	ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial
	EDGAR Online (Tue, Feb 2)

•	Achillion rises on hepatitis/HIV drug pact
	AP (Tue, Feb 2)

•	Achillion shares rise on drug development deal in China
	at Reuters (Tue, Feb 2)

•	Achillion Pharma upgraded by Wedbush Morgan
	Briefing.com (Tue, Feb 2)

•	Flextronics, Columbia Laboratories: Midday Volume Plays
	at TheStreet.com (Thu, Jan 28)

•	Recent Dividend Hikes May Point to a Return to Normalcy
	at Seeking Alpha (Sun, Jan 24)

•	Pharma Stocks Close Down On Two Offerings
	at Forbes.com (Fri, Jan 22)

•	Plunging Pharmas Offer Falling Stock
	at Forbes.com (Fri, Jan 22)

More Headlines for ACHN...

ANALYST

EPS Est (next year) (Dec-07) :	-1.87
EPS Est (in 2 years) (Dec-08) :	-1.63
Avg Rec (current)*:	1.6
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases.

Full Company Profile

Add to Portfolio

Email to a Friend

•